Search | IOVS | ARVO Journals

Showing 1 – 20 of 20

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract April 2011

12-months Results Of Riboflavin/ultraviolet A Corneal Collagen Cross-linking (CXL) For Keratoconus In Patients With Thin Corneas

Franz Prager; Gerald Schmidinger

Invest. Ophthalmol. Vis. Sci.. 2011; 52(14):5199.

ARVO Annual Meeting Abstract April 2010

Preliminary Long-Term Results After Endokeratoplasty

F. Prager; G. Schmidinger; M. L. Reiter; C. Skorpik

Invest. Ophthalmol. Vis. Sci.. 2010; 51(13):759.

Retina April 2010

Imaging of the Retinal Pigment Epithelium in Age-Related Macular Degeneration Using Polarization-Sensitive Optical Coherence Tomography

PDF

Christian Ahlers; Erich Götzinger; Michael Pircher; Isabelle Golbaz; Franz Prager; Christopher Schütze; Bernhard Baumann; Christoph K. Hitzenberger; Ursula Schmidt-Erfurth
TAGS: age-related macular degeneration, atrophy, diagnostic imaging, optical coherence tomography, retinal pigment epithelium, drusen, cicatrix, body tissue
Invest. Ophthalmol. Vis. Sci.. 2010; 51(4):2149-2157. https://doi.org/10.1167/iovs.09-3817

ARVO Annual Meeting Abstract April 2009

Morphological Characteristics of Idiopathic Juxtafoveolar Teleangiectasia Using Polarization-Sensitive Optical Coherence Tomography

C. Schuetze; B. Baumann; C. Ahlers; M. Pircher; E. Götzinger; S. Sacu; F. Prager; G. Matt; C. K. Hitzenberger; U. Schmidt-Erfurth

Invest. Ophthalmol. Vis. Sci.. 2009; 50(13):343.

ARVO Annual Meeting Abstract April 2009

Polarization-Sensitive Optical Coherence Tomography in Adult-Onset Foveomacular Vitelliform Dystrophy

F. Prager; E. Goetzinger; C. Ahlers; M. Pircher; B. Baumann; W. Geitzenauer; C. Schütze; C. Hitzenberger; U. Schmidt-Erfurth

Invest. Ophthalmol. Vis. Sci.. 2009; 50(13):762.

ARVO Annual Meeting Abstract April 2009

Morphological Characteristics and Clinical Comparison of Autofluorescence and Polarization-Sensitive Optical Coherence Tomography in Geographic Atrophy

C. Ahlers; B. Baumann; M. Pircher; E. Götzinger; C. Schuetze; R. Sayegh; F. Prager; F. Schlanitz; C. K. Hitzenberger; U. M. Schmidt-Erfurth

Invest. Ophthalmol. Vis. Sci.. 2009; 50(13):3918.

Biochemistry and Molecular Biology March 2009

Intraocular Concentrations of Growth Factors and Cytokines in Retinal Vein Occlusion and the Effect of Therapy with Bevacizumab

PDF

Marion Funk; Katharina Kriechbaum; Franz Prager; Thomas Benesch; Michael Georgopoulos; Gerhard J. Zlabinger; Ursula Schmidt-Erfurth
TAGS: bevacizumab, cytokine, growth factor, retinal vein occlusion, vascular endothelial growth factor a
Invest. Ophthalmol. Vis. Sci.. 2009; 50(3):1025-1032. https://doi.org/10.1167/iovs.08-2510

ARVO Annual Meeting Abstract May 2008

Intravitreal Bevacizumab (Avastin®) Monotherapy versus Photodynamic Therapy Plus Intravitreal Triamcinolone for Neovascular Age-Related Macular Degeneration:12 Months Results of a Prospective, Randomized, Controlled Clinical Trial

F. Prager; S. Michels; S. Sacu; G. Weigert; R. Dunavölgyi; W. Geitzenauer; U. Schmidt-Erfurth

Invest. Ophthalmol. Vis. Sci.. 2008; 49(13):1168.

ARVO Annual Meeting Abstract May 2008

New Perspectives in the Imaging of Age-Related Macular Degeneration by Polarization Sensitive Optical Coherence Tomography

C. Ahlers; E. Goetzinger; M. Pircher; I. Golbaz; F. Prager; R. Sayegh; B. Baumann; C. Hitzenberger; U. Schmidt-Erfurth

Invest. Ophthalmol. Vis. Sci.. 2008; 49(13):1176.

ARVO Annual Meeting Abstract May 2008

Aqueous Humor Concentrations of Growth Factors and Cytokines in Retinal Vein Occlusion and the Effect of Therapy With Bevacizumab

M. Funk; K. Kriechbaum; F. Prager; M. Georgopoulos; G. Zlabinger; U. Schmidt-Erfurth

Invest. Ophthalmol. Vis. Sci.. 2008; 49(13):4571.

ARVO Annual Meeting Abstract May 2008

Spectral Domain Optical Coherence Tomography and Microperimetry for Documentation of Retinal Morphology and Function Following Antiangiogenic Treatment of Retinal Vein Occlusion

K. Kriechbaum; F. Prager; W. Geitzenauer; C. Simader; C. Schuetze; G. Stock; M. Funk; U. Schmidt-Erfurth

Invest. Ophthalmol. Vis. Sci.. 2008; 49(13):2691.

ARVO Annual Meeting Abstract May 2007

Intravitreal Bevacizumab (Avastin®) in Patients With Bilateral, Idiopathic, Acquired Parafoveolar Telangiectasis (2A)

C. Simader; S. Michels; F. Prager; W. Geitzenauer; M. Georgopoulos; K. Polak; U. Schmidt-Erfurth

Invest. Ophthalmol. Vis. Sci.. 2007; 48(13):4146.

ARVO Annual Meeting Abstract May 2007

Stratus® and High-Definition Optical Coherence Tomography for Evaluation of Anti-VEGF Therapy in Patients With Neovascular Age-Related Macular Degeneration

W. Geitzenauer; S. Michels; G. Weigert; F. Prager; C. Ahlers; M. Bolz; U. Schmidt-Erfurth

Invest. Ophthalmol. Vis. Sci.. 2007; 48(13):2596.

ARVO Annual Meeting Abstract May 2007

Intravitreal Bevacizumab (Avastin®) in Retinal Vein Occlusion - A Six Months Follow Up

K. Kriechbaum; S. Michels; F. Prager; M. Georgopoulos; M. Funk; K. Polak; C. Hirn; U. Schmidt-Erfurth

Invest. Ophthalmol. Vis. Sci.. 2007; 48(13):308.

ARVO Annual Meeting Abstract May 2007

Comparison of 2.5 and 5mg/kg Systemic Bevacizumab (Avastin®) in Patients With Neovascular Age-Related Macular Degeneration

F. Prager; S. Michels; W. Geitzenauer; L. Vormittag; G. Kornek; P. J. Rosenfeld; U. Schmidt-Erfurth

Invest. Ophthalmol. Vis. Sci.. 2007; 48(13):1825.

ARVO Annual Meeting Abstract May 2006

Standard vs. Reduced Dose Systemic Bevacizumab (Avastin®) for the Treatment of Neovascular Age–Related Macular Degeneration

S.M. Michels; P.J. Rosenfeld; W. Geitzenauer; F. Prager; A. Rosin; G. Kornek; L. Vormittag; U. Schmidt–Erfurth

Invest. Ophthalmol. Vis. Sci.. 2006; 47(13):5231.

ARVO Annual Meeting Abstract May 2006

Evaluating Effects of Systemic Bevacizumab (Avastin®) on Pigment Epithelial Detachment in Neovascular Age–Related Macular Degeneration

M. Bolz; S. Michels; W. Geitzenauer; F. Prager; U. Schmidt–Erfurth

Invest. Ophthalmol. Vis. Sci.. 2006; 47(13):5234.

ARVO Annual Meeting Abstract May 2006

Comparison of Early Response to Systemic or Intravitreal Bevacizumab (Avastin®) in Patients With Neovascular AMD

F. Prager; S. Michels; W. Geitzenauer; U. Schmidt–Erfurth

Invest. Ophthalmol. Vis. Sci.. 2006; 47(13):5245.

ARVO Annual Meeting Abstract May 2006

Anterior Chamber Inflammatory Activity in Patients With Neovascular Age–Related Macular Degeneration Treated With Intravitreal Bevacizumab (Avastin®)

C.G. Kiss; S. Michels; W. Geitzenauer; F. Prager; U. Schmidt–Erfurth

Invest. Ophthalmol. Vis. Sci.. 2006; 47(13):2171.

ARVO Annual Meeting Abstract May 2006

VEGF 165 Serum Levels Following Systemic Bevacizumab (Avastin®) Therapy for Neovascular Age–Related Macular Degeneration

A.M. Rosin; S. Michels; W. Geitzenauer; F. Prager; U. Schmidt–Erfurth

Invest. Ophthalmol. Vis. Sci.. 2006; 47(13):2173.

NARROW

Content Type

Journal

Article Type

Topics

Tags

Specify Date Range

12-months Results Of Riboflavin/ultraviolet A Corneal Collagen Cross-linking (CXL) For Keratoconus In Patients With Thin Corneas

Preliminary Long-Term Results After Endokeratoplasty

Imaging of the Retinal Pigment Epithelium in Age-Related Macular Degeneration Using Polarization-Sensitive Optical Coherence Tomography

Morphological Characteristics of Idiopathic Juxtafoveolar Teleangiectasia Using Polarization-Sensitive Optical Coherence Tomography

Polarization-Sensitive Optical Coherence Tomography in Adult-Onset Foveomacular Vitelliform Dystrophy

Morphological Characteristics and Clinical Comparison of Autofluorescence and Polarization-Sensitive Optical Coherence Tomography in Geographic Atrophy

Intraocular Concentrations of Growth Factors and Cytokines in Retinal Vein Occlusion and the Effect of Therapy with Bevacizumab

Intravitreal Bevacizumab (Avastin®) Monotherapy versus Photodynamic Therapy Plus Intravitreal Triamcinolone for Neovascular Age-Related Macular Degeneration:12 Months Results of a Prospective, Randomized, Controlled Clinical Trial

New Perspectives in the Imaging of Age-Related Macular Degeneration by Polarization Sensitive Optical Coherence Tomography

Aqueous Humor Concentrations of Growth Factors and Cytokines in Retinal Vein Occlusion and the Effect of Therapy With Bevacizumab

Spectral Domain Optical Coherence Tomography and Microperimetry for Documentation of Retinal Morphology and Function Following Antiangiogenic Treatment of Retinal Vein Occlusion

Intravitreal Bevacizumab (Avastin®) in Patients With Bilateral, Idiopathic, Acquired Parafoveolar Telangiectasis (2A)

Stratus® and High-Definition Optical Coherence Tomography for Evaluation of Anti-VEGF Therapy in Patients With Neovascular Age-Related Macular Degeneration

Intravitreal Bevacizumab (Avastin®) in Retinal Vein Occlusion - A Six Months Follow Up

Comparison of 2.5 and 5mg/kg Systemic Bevacizumab (Avastin®) in Patients With Neovascular Age-Related Macular Degeneration

Standard vs. Reduced Dose Systemic Bevacizumab (Avastin®) for the Treatment of Neovascular Age–Related Macular Degeneration

Evaluating Effects of Systemic Bevacizumab (Avastin®) on Pigment Epithelial Detachment in Neovascular Age–Related Macular Degeneration

Comparison of Early Response to Systemic or Intravitreal Bevacizumab (Avastin®) in Patients With Neovascular AMD

Anterior Chamber Inflammatory Activity in Patients With Neovascular Age–Related Macular Degeneration Treated With Intravitreal Bevacizumab (Avastin®)

VEGF 165 Serum Levels Following Systemic Bevacizumab (Avastin®) Therapy for Neovascular Age–Related Macular Degeneration

To View More...

You must be signed into an individual account to use this feature.